CAMBRIDGE, Mass. – Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced a clinical trial collaboration with Roche to evaluate SRF388, Surface’s investigational anti-IL-27 antibody, in combination with Roche’s atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab...
Latest News
A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don’t require immediate surgery to remove the primary tumor in the colon. Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) presented their data today at the American...
Leipzig, Germany – Two decades ago, Professor Michael Höckel, then Director of the Department of Gynaecology at Leipzig University, developed a new surgical method for the treatment of cervical cancer patients: total mesometrial resection (TMMR). The method is based on the ontogenetic cancer field model, which predicts the localgyne spreading...
Abstract Adolescent idiopathic scoliosis (AIS) is a three-dimensional growth disorder. Corrective surgical procedures are the recommended treatment option for a thoracic angle exceeding 50° and a lumbar major curve of 40°. Over the past few years, dynamic growth modulation implants have been developed as alternatives to permanent fusion. The ApiFix...
Zürich, Switzerland – People living with RMDs can now fill out the survey online, sharing their experiences to help build a comprehensive understanding of their disease’s impact. The data collected will be invaluable for researchers, healthcare professionals, and patients themselves, providing insights into the burden of RMDs and identifying areas...
KYLE — After learning that he had a second chance at life, Brandon Higgins wanted to contribute something great for his community. The Kyle resident contracted the rare Rocky Mountain Spotted Fever (RMSF), which is spread through the bite of an infected tick, in 2006 while he was a junior...
Ingelheim am Rhein, Germany – Boehringer Ingelheim today announced that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase II trial [response difference: 64.8% (CI 51.1% – 78.6%), p<0.0001]. The trial met its...
Boston, MASS – Bronchiectasis, a condition defined by widened lung airways, cough and sputum production, and frequent infections, often presents along with chronic obstructive pulmonary disease (COPD). This overlap is associated with airflow obstruction and higher mortality in adults. As healthcare systems now provide access to lung image data more...
SOUTH SAN FRANCISCO, Calif. — Sutro Biopharma, Inc (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the randomized portion (Part 2) of REFRαME-O1, the registration-directed trial of luveltamab tazevibulin (luvelta) in platinum-resistant ovarian cancer (PROC), is now open for enrollment, and...
SOUTH SAN FRANCISCO, Calif. — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported its financial results for the first quarter of 2023, its recent business highlights, and a preview of select anticipated milestones. “We’ve had a...